Tandem Diabetes Care (Nasdaq:TNDM) has shared new findings supporting the use of its Control-IQ technology in type 1 diabetes ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...

SAN DIEGO, Calif.--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of ...

Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...

Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...

Positive clinical trial results for the Control-IQ algorithm from Tandem Diabetes Care presented at the American Diabetes Association meeting earlier this month positions the company to continue its ...

Investors counting on the company's dominance of the closed-loop artificial pancreas market might want to temper their expectations. The rub is that rivals are already nipping at Tandem's heels. In ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In June, the FDA approved the use of the Tandem Diabetes ...